Ensartinib

FDA approved ensartinib for ALK-positive NSCLC after phase 3 eXALT3 trial results. Ensartinib showed longer median PFS (25.8 months) vs crizotinib (12.7 months). Common AEs included rash, musculoskeletal pain, and constipation. No new safety signals observed.

© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

Xcovery Holdings, Inc. announced FDA approval of ensartinib for ALK-positive locally advanced or metastatic NSCLC, based on Phase III eXalt3 trial data showing improved PFS over crizotinib. Ensartinib is a next-gen ALK inhibitor developed by Xcovery and Betta Pharmaceuticals.

Xcovery Holdings, Inc. announced FDA approval of ensartinib for ALK-positive NSCLC treatment, based on Phase III eXalt3 trial results showing improved progression-free survival over crizotinib. Ensartinib, a next-gen ALK inhibitor, offers a new first-line treatment option, reflecting Xcovery's commitment to advancing precision medicine in cancer care.

On Dec. 18, 2024, FDA approved Ensacove (ensartinib) for ALK-positive NSCLC patients without prior ALK-targeted therapy. Based on eXALT3 study, Ensacove showed significant progression-free survival improvement over Xalkori, with no overall survival difference. Contact healthcare for more info.

FDA approved ensartinib for ALK-positive NSCLC, a first-choice treatment for untreated patients with locally advanced or metastatic disease. Ensartinib, a second-generation ALK inhibitor, improves progression-free survival to 25.8 months vs. 12.7 months for crizotinib, with common side effects including cough, itching, and rash.

FDA approved ensartinib for ALK-positive advanced NSCLC, showing improved PFS vs crizotinib in phase 3 study. Ensartinib, manufactured by Xcovery and Betta, offers a new first-line treatment option with manageable AEs and potential cost-effectiveness.